80
views
0
recommends
+1 Recommend
0 collections
    16
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Public awareness of cancer in Britain: a population-based survey of adults

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective:

          To assess public awareness of cancer warning signs, anticipated delay and perceived barriers to seeking medical advice in the British population.

          Methods:

          We carried out a population-based survey using face-to-face, computer-assisted interviews to administer the cancer awareness measure (CAM), a newly developed, validated measure of cancer awareness. The sample included 2216 adults (970 males and 1246 females) recruited as part of the Office for National Statistics Opinions Survey using stratified probability sampling.

          Results:

          Awareness of cancer warning signs was low when open-ended (recall) questions were used and higher with closed (recognition) questions; but on either measure, awareness was lower in those who were male, younger, and from lower socio-economic status (SES) groups or ethnic minorities. The most commonly endorsed barriers to help seeking were difficulty making an appointment, worry about wasting the doctor's time and worry about what would be found. Emotional barriers were more prominent in lower SES groups and practical barriers (e.g. too busy) more prominent in higher SES groups. Anticipated delay was lower in ethnic minority and lower SES groups. In multivariate analysis, higher symptom awareness was associated with lower anticipated delay, and more barriers with greater anticipated delay.

          Conclusions:

          A combination of public education about symptoms and empowerment to seek medical advice, as well as support at primary care level, could enhance early presentation and improve cancer outcomes.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

          EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in 23 European countries, diagnosed in 1995-1999 and followed to December 2003. For each cancer site, the mean European area-weighted observed and relative survival at 1-, 3-, and 5-years by age and sex are presented. Country-specific 1- and 5-year relative survival is also shown, together with 5-year relative survival conditional to surviving 1-year. Within-country variation in survival is analysed for selected cancers. Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis (breast, colorectum, stomach, skin melanoma), was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia. France, Switzerland and Italy generally had high survival, slightly below that in the northern countries. There were between-region differences in the survival for haematologic malignancies, possibly due to differences in the availability of effective treatments. Survival of elderly patients was low probably due to advanced stage at diagnosis, comorbidities, difficult access or lack of availability of appropriate care. For all cancers, 5-year survival conditional to surviving 1-year was higher and varied less with region, than the overall relative survival.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Attitudes and the Attitude-Behavior Relation: Reasoned and Automatic Processes

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Influence of delay on survival in patients with breast cancer: a systematic review.

              Most patients with breast cancer are detected after symptoms occur rather than through screening. The impact on survival of delays between the onset of symptoms and the start of treatment is controversial and cannot be studied in randomised controlled trials. We did a systematic review of observational studies (worldwide) of duration of symptoms and survival. We identified 87 studies (101,954 patients) with direct data linking delay (including delay by patients) and survival. We classified studies for analysis by type of data in the original reports: category I studies had actual 5-year survival data (38 studies, 53,912 patients); category II used actuarial or multivariate analyses (21 studies, 25,102 patients); and category III was all other types of data (28 studies, 22,940 patients). We tested the main hypothesis that longer delays would be associated with lower survival, and a secondary hypothesis that longer delays were associated with more advanced stage, which would account for lower survival. In category I studies, patients with delays of 3 months or more had 12% lower 5-year survival than those with shorter delays (odds ratio for death 1.47 [95% CI 1.42-1.53]) and those with delays of 3-6 months had 7% lower survival than those with shorter delays (1.24 [1.17-1.30]). In category II, 13 of 14 studies with unrestricted samples showed a significant adverse relation between longer delays and survival, whereas four of five studies of only patients with operable disease showed no significant relation. In category III, all three studies with unrestricted samples supported the primary hypothesis. The 13 informative studies showed that longer delays were associated with more advanced stage. In studies that controlled for stage, longer delay was not associated with shorter survival when the effect of stage on survival was taken into account. Delays of 3-6 months are associated with lower survival. These effects cannot be accounted for by lead-time bias. Efforts should be made to keep delays by patients and providers to a minimum.
                Bookmark

                Author and article information

                Journal
                Br J Cancer
                British Journal of Cancer
                Nature Publishing Group
                0007-0920
                1532-1827
                03 December 2009
                03 December 2009
                03 December 2009
                : 101
                : S2
                : S18-S23
                Affiliations
                [1 ]Cancer Research UK Health Behaviour Research Centre, Department of Epidemiology and Public Health, UCL Gower Street, London WC1E 6BT, UK
                [2 ]Cancer Research UK Promoting Early Presentation Group, Institute of Psychiatry, King's College London, St Thomas' Hospital London, UK
                [3 ]General Practice and Primary Care, Division of Community Based Sciences, Faculty of Medicine 1 Horselethill Road, Glasgow, UK
                [4 ]Cancer Research UK Primary Care Education Research Group, Cancer Epidemiology Unit, University of Oxford Richard Doll Building, Roosevelt Drive, Oxford, UK
                [5 ]Health Information Department, Cancer Research UK 61 Lincoln's Inn Fields, London, UK
                Author notes
                [* ]Author for correspondence: j.wardle@ 123456ucl.ac.uk
                Article
                6605386
                10.1038/sj.bjc.6605386
                2790705
                19956158
                ea73b07c-c717-4c21-8c12-770313e425a7
                Copyright 2009, Cancer Research UK
                History
                Categories
                Papers

                Oncology & Radiotherapy
                anticipated delay,barriers,symptom awareness,cancer awareness,cancer warning signs

                Comments

                Comment on this article